• Cannabis-infused chocolates and candies, such as gummies, will be manufactured using LXRP’s next-generation, patented technology to be sold in Canada and internationally, where permitted
• LXRP’s goal is to partner with manufacturers who provide best-in-class products to existing large consumer groups
• Licensing DehydraTECH™ is key to LXRP’s generation of revenue; LXRP aims to license its IP in all countries where its technology is patented or patent pending

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) continues to generate revenue from licensing its proprietary and patented technology DehydraTECH™, which is already patented in the U.S. and Australia. The company also has multiple patents pending in more than 40 countries globally.

Lexaria’s entry into a seven-year definitive licensing agreement with Cannfections Group, Inc. in Canada is a major step toward bringing its improved delivery methodologies to market (http://ibn.fm/F5w4w). DehydraTECH promotes healthier ingestion methods and lower overall dosing. Cannfections is expected to leverage the platform by manufacturing and marketing cannabis-infused chocolates and candies for the legalized adult market.

Cannfections contract manufactures chocolate retail products for several international and domestic chocolate brands. The company believes that the agreement should lead not only to new product entries for Canadian cannabis edibles, but to exports to international markets, where permitted. In addition, the agreement permits LXRP to offer other licensee partners the option of using Cannfection’s manufacturing expertise to produce cannabis-infused chocolates and gummies powered by DehydraTECH technology.

DehydraTECH has been shown to increase intestinal absorption rates and provide for more rapid delivery of active ingredients to the bloodstream. It also offers taste-masking benefits for orally-administered molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs and nicotine.

“By licensing our technology to Cannfections, Lexaria can now offer its commercial clients the expertise of one of Canada’s oldest and most established chocolatiers utilizing next-generation DehydraTECH technology,” Chris Bunka, CEO of Lexaria, stated in a news release. “This is a long term strategic relationship meant to offer technology, value and expertise to Licensed Producers wanting to offer the highest quality chocolate edibles available in Canada once permitted under Health Canada regulations.”

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Company committed to scientific validation of CBD efficacy
• Produces, markets and sells only the highest quality Full-Spectrum Hemp Oil containing CBD
• With new subsidiaries and acquisition, future is increasingly bright

Building on vast anecdotal and mounting scientific evidence, the market for cannabidiol (CBD) products is exploding across the globe. The discovery of the human endocannabinoid system in the 1990s has intensified research and validated many of the anecdotal reports of CBD effectiveness in treating a variety of physical ailments.

Seizing on the immense market opportunity and substantiating efficacy with science, Earth Science Tech, Inc. (OTC: ETST) is focused on the science, research and studies of its high grade hemp CBD oil as a nutraceutical and dietary supplement. Earth Science already markets and sells some of the highest quality and purity Full Spectrum Hemp Oil containing CBD available. The company’s products are formulated using superior supercritical CO2 cold liquid extraction, through which the cannabinoids are kept at the rawest state possible in order to maintain essential therapeutic properties.

Earth Science believes that science is the foundation for the future of not only its high grade hemp CBD oil and its array of products, but also the entire global CBD market. In a commitment to the underlying science, Earth Science has established a research agreement with the University of Central Oklahoma and DV Biologics Laboratory to study and advance the health care benefits of its high grade hemp CBD oil. Research has already indicated that Earth Science CBD nutritional and dietary supplement products are at the top in the industrial hemp space. The company is committed to providing the public with sound scientific research and up-to-date information on the progress of studies being done on its high grade hemp CBD products.

In 2017, Earth Science launched two new subsidiaries, KannaBidioid Inc., to manufacture and distribute vapes/e-liquids and gummy edibles, and Cannabis Therapeutic Inc., to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products based on its existing CBD patent. The company also acquired Canna Inno Laboratories Inc., which will allow it access to the burgeoning Canadian market and government grants.

Earth Science’s multi-faceted, science-based approach to the development, manufacture and sale of high quality CBD products places the company in a unique and enviable position headed into 2018 and beyond. As Chief Science Officer Michel Aubé, PhD, stated in a January 3, 2018, press release (http://ibn.fm/E9RPh), “[W]e will clearly be recognized as a leader in cannabinoids research and other health science research arena. Our future is shining bright.”

For more information, visit the company’s website at www.EarthScienceTech.com

• Companies in partnership to create cannaBLOX, a blockchain-based software smart contract platform for the legalized cannabis industry
• cannaBLOX blockchain software is a supply chain management platform designed to ease logistical bottlenecks, minimize fraud, assist in taxation and ensure regulatory compliance
• LIBFF and BLLXF have completed preliminary input and analysis in their joint phase one development of cannaBLOX

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) and Blox Labs, Inc. (CSE: BLOX) (OTC: BLLXF) have announced progress on their joint development of phase one of cannaBLOX, the blockchain-based smart contract platform for the legalized cannabis industry (http://ibn.fm/zAMRV).

Blox Labs is working to complete its white paper on cannaBLOX, and a satellite development team has been created in Eastern Europe that specializes in blockchain and decentralized application technologies. The initial framework and analysis segment of the white paper is now complete.

The white paper includes cannabis industry analysis, schematic design, project scoping and itemizing utility and process flow details. The new development team is specialized in omni-language development in Ethereum.

LIBFF is a Canada-based company which has a focus on building a portfolio of cannabis-related businesses. In this sector, it is targeting cultivation, processing and the development of CBD/THC pet and supply-chain products. Its portfolio includes a 100 percent interest in North Road Ventures and a 60 percent interest in Just Kush, strengthening LIBFF’s position as a vertically-integrated cannabis company. North Road is an emerging distributor of cultivated and manufactured cannabis products to licensed retailers. Just Kush is a late-stage applicant for Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”).

Blox Labs developments include software for blockchain, smart contracts and decentralized application technologies. It is entering the Canadian cannabis market with cannaBLOX software, a blockchain solution targeted at cannabis seed-to-sale verification.

For more information, visit the company’s website at www.LibLeaf.ca

Let us hear your thoughts: Liberty Leaf Holdings Ltd. Message Board

• Company recently acquired Google Play Store app ‘Bitcoin Altcoins Tracker’
• New app enables tracking and support for 1,600+ cryptocurrencies and conversion into 50+ native currencies
• New features announced for ZenaPay; new version announced for CryptoFolio

Continuing a strong year that has already been marked by various notable developments, Epazz, Inc. (OTC: EPAZ) announced on February 20 (http://ibn.fm/hIFV1) that it has acquired ‘Bitcoin Altcoins Tracker’, an app that’s currently available for download on the Google Play Store (http://ibn.fm/sOEyl). This further expands the company’s robust portfolio of blockchain apps.

The Bitcoin Altcoins Tracker app, currently sold for $2.49 per download, is able to track and support more than 1,600 cryptocurrencies and offers conversion into more than 50 native currencies.

Features of the app are expected be included in Epazz’s CryptoFolio blockchain mobile app, which the company acquired in January (http://ibn.fm/HqWiO), and a new version of CryptoFolio is scheduled to be released on May 30. This new version is set to include all features from Bitcoin Charts and Bitcoin Altcoins Tracker, with the combined app offered in a free edition (supported by advertisement revenue) and a paid edition that will be sold for $2.49. There will also be an option for users to purchase additional features, ranging in price from $1.99 to $5.99.

The company’s acquisition of Bitcoin Altcoins Tracker will give CryptoFolio users the benefit of cryptocurrency conversions into native currencies.

Epazz’s portfolio of blockchain apps continues to expand, aiding in cross sales and upsales for the company. Users of Epazz’s ZenaPay will be given the option to make in-app purchases using the CryptoFolio app, and ZenaPay users will further be given a discount for using CryptoFolio.

In other recent news from Epazz, the company has released details regarding the future release of new features for its ZenaPay payment solution, which is being developed to solve payment issues for high-risk industries, including offering a bitcoin payment software that lets consumers utilize digital currency to complete online and in-store purchases.

Upcoming features in the works for ZenaPay include an iPad point-of-sale app to be integrated with the ZenaPay Merchant App; a vendor payment solution that will enable merchant businesses to pay their vendors and employees via cryptocurrency; an e-commerce store; seed-to-sale tracking; and sales reporting and compliance.

For more information, visit the company’s website at www.Epazz.com

Let us hear your thoughts: Epazz, Inc. Message Board

• Petroteq launched its PetroBLOQ blockchain platform – a pioneering development in the oil and gas industry
• Mexico’s Pemex has already become the first PetroBLOQ member
• The blockchain market is set to experience colossal growth in all industries over the next six years

Blockchain technology has a wide range of applications across different industries, and Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF), a leading developer and provider of proprietary technology for the energy industry, has just demonstrated one more. The company’s innovative PetroBLOQ blockchain platform is a pioneer development in the oil and gas industry, aiming to take the shared economy concept one step further by making a number of industry intermediaries redundant and, consequently, reducing the cost of transactions in supply chain management (http://ibn.fm/dv96m).

Through the use of blockchain technology, it’s possible to complete transactions without an intermediary because of the verified procedures that are built into the platform. This is the main difference between blockchain-based projects and peer-to-peer interactions like those typical for sharing economy flagships such as Airbnb and Uber.

Blockchain technology makes it possible for data about every single interaction to be stored as a digital ledger in a continually reconciled database. Each reconciled transaction becomes a block – the unit that is needed to ensure the integrity of the transaction. This is how the intermediary can be eliminated altogether. The process ensures fairness and cost-efficiency while also expediting the completion of transactions.

According to Petroteq Energy, the oil and gas industry can benefit immensely from the introduction of blockchain technology. The structure of oil and gas interactions is complex. The industry spans across countries and continents and involves multiple players – from domestic transportation entities to refineries and information technology units. Because of the behemoth structure, the accumulation of accurate transaction data in real-time becomes a challenging, almost impossible task. This is where blockchain platforms like PetroBLOQ can be utilized to simplify complex steps and bring immediacy to the table.

All transactions across this massive network can be verified immediately via a blockchain platform. A central reconciling authority is no longer needed to examine the data. Obviously, the elimination of such an authority can increase the cost-efficiency of transactions, ensure data security and enhance the entire data management process.

This isn’t the only blockchain-related initiative launched by Petroteq Energy. In 2017, the company announced its entry into the Enterprise Ethereum Alliance (EEA). This is the biggest open-source blockchain network in the world, and its members include more than 500 companies and experts in the field of Ethereum technology.

Already expanding at an exponential rate, the global blockchain market is expected to continue growing in the years to come. While, in 2016, it was estimated at $210.2 million in the U.S., this market is set to increase to $2.3 billion dollars by 2021 (http://ibn.fm/pzNFY). Other, more daring predictions set a global blockchain market size of $7.74 billion by 2024 (http://ibn.fm/Xr2ZQ).

As of 2017, 80 percent of banks have developed their own blockchain technologies (http://ibn.fm/bQXc3). It’s nothing but natural for such platforms to start shaping up interactions in industries other than finance. A 2016 study by Deloitte (http://ibn.fm/mH16h) showed that many representatives of the oil and gas industry were still hesitant about blockchain introduction. Such attitudes leave the door for innovation wide open, enabling companies like Petroteq Energy to launch their pioneer developments.

PetroBLOQ is already making some change. Shortly after the initial announcement, Petroteq Energy reps said that Mexico’s state-owned petroleum company, Pemex, has agreed to become the first PetroBLOQ member. The security of the platform will make it easier to overcome and stabilize fluctuations stemming from the political climate and unforeseen circumstances.

For more information, visit the company’s website at www.Petroteq.energy

Let us hear your thoughts: Petroteq Energy Inc. Message Board

• Skinvisible’s DermSafe® hand sanitizer provides long-term protection against viruses
• Patented technology delivers active ingredients topically
• Company generates revenue from four income streams

An outbreak of the deadly influenza A (H3N2) virus has devastated families across the United States this winter. Traditionally, the elderly and the very young are most vulnerable to the flu, but, this time around, it is attacking people of all ages. This outbreak follows on the heels of the potent H7N9 avian influenza virus, which has the potential to spread globally, although largely confined to China at present. Hand hygiene is vital to reduce the risk of contracting these flu strains. Skinvisible, Inc. (OTCQB: SKVI) has developed a unique hand sanitizer, DermSafe®, which offers long-term protection against harmful microbes.

DermSafe® uses patented polymer delivery technology developed by Skinvisible called Invisicare®. This proprietary technology binds active ingredients to the skin to enhance their delivery and resists wash-off and rub-off for up to four hours, even with hand washing. It creates a barrier to prevent attack by viruses and damage from toxins, retaining moisture in the skin while allowing normal respiration and perspiration. Left on the skin to do their job, Invisicare® formulations eventually wear off as part of the skin’s natural exfoliation process.

All of Skinvisible’s products utilizing Invisicare® technology are non-drying, as the formulations do not contain any organic solvents such as alcohol, silicones or waxes. Enhanced delivery means a lower dosage of active ingredients is required while still offering improved efficacy, reduced skin irritation and longer duration of action. To validate its marketing claims, the company uses FDA-registered independent laboratories to verify the efficiency of its products.

Through wholly-owned subsidiary Kintari, Skinvisible has developed a range of anti-aging products, including day cream, night cream, sunscreen and hand and body lotion. All of these products use the patented Invisicare® topical delivery technology. The company has 14 global patents for over 40 skincare products powered by Invisicare®. The Kintari website (www.Kintari.com) is a marketing portal for its products, offering consumers the ability to purchase these patented products online.

Looking ahead, Skinvisible’s development pipeline using Invisicare’s topical delivery technology includes products for acne, dermatitis, skin cancer, warts and first-aid pain relief, as well as formulations with anti-aging, anti-fungal and anti-inflammatory properties. In November 2017, the company issued a letter of intent to merge with Quoin Pharmaceuticals Limited, a developer of post-surgical pain relief products that replace or reduce opioid use. Quoin is also developing a transdermal formulation for anti-depression treatment of military veterans showing suicidal tendencies related to post-traumatic stress disorder (PTSD).

Skinvisible’s business model provides four revenue streams. By licensing its formulations, the company generates research and development fees for new products. It also charges license fees to secure exclusive territorial rights to a product, while generating ongoing royalties based on a licensee’s sales. Direct revenue is generated from the sale of Kintari products and the sale of the company’s Invisicare® polymers to its clients.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

• Global testing services market expected to achieve 10 percent-plus CAGR growth
• California cannabis testing market also set for exponential increase
• EVIO to double national testing footprint to 18 labs

California, befitting its history as part of America’s westward expansion, has earned an appellation as the ‘Wild West’ of pot. Medical marijuana, legal in the state since 1996, has been largely bypassed by quality control and safety regulations. That is about to change. To coincide with the opening of the adult recreational market, a plethora of rules and rubrics has been issued. California MMJ businesses will have until July 2018 to ensure compliance. As a result, demand for cannabis testing services in California is set to increase rapidly, a development that means EVIO, Inc. (OTCQB: EVIO), which has acquired testing facilities in Berkeley, California, is in the right place at the right time.

The supply shortfall in California cannabis testing services is rising to crisis proportions at a time when one report warns that ‘much of the marijuana sold in dispensaries in California would fail safety standards in other states’ (http://ibn.fm/nXnjU). Quality issues plague the industry, as recent examples from further afield demonstrate. A couple of MMJ companies licensed under Canada’s ACMPR were found to be using banned pesticides, and a cancer patient died after acquiring a fungal contamination, which was said to have originated in smoked marijuana.

Despite this alarming state of affairs, there are only 22 testing laboratories operating in the state (http://ibn.fm/t9mH3). However, where there is crisis, there is also opportunity, and EVIO has been quick to recognize this. Earlier this year, the company announced that it was acquiring C3 Labs in Berkeley, California, which will give it a presence in the Bay Area to go along with its labs in Southern California and north of Sacramento. This will bring the number of labs operated by the company to nine in five states. These include four in Oregon, two in Florida, and one each in California, Colorado and Massachusetts.

Reporting on data compiled by Markets and Markets, High Times recently commented that ‘cannabis lab testing for potency, purity and detailed information such as terpene counts was worth $866 million in 2016.’ By 2021, the global testing services market is expected to hit $1.4 billion, representing a CAGR of more than 10 percent. Driven by such a powerful tailwind, EVIO is set for further revenue growth. The company saw testing services revenues for the nine months to June 30, the last reported period, climb 1,100 percent year-over-year in 2017 to $2.1 million. Now, through testing subsidiary EVIO Labs, the company plans to open 18 laboratories by the end of 2018 at locations throughout the United States.

EVIO is headed by William Waldrop, MBA, chairman and CEO. Waldrop, a co-founder of EVIO Labs’ parent company, spearheaded the acquisition of the company’s first analytical laboratory facility in Bend, Oregon. He has since grown the company to its present five labs and nine operating locations, and he is the driving force behind the nationwide rollout of EVIO Labs.

Previously, Waldrop was chairman and CEO of Newport Entertainment Group and president and COO of College Partnership, a publicly traded company that provided student services. In addition, while working as a senior manager at AirTouch Cellular, he led the team that, in just four years, built a 44-store distribution channel generating over $100 million in annual revenues. As vice president of operations for Leading Edge Broadband, he oversaw the design and roll-out of a global telecommunications sales and outreach network. Waldrop has also provided advisory services to several public companies.

For more information, visit the company’s website at www.EVIOLabs.com

Let us hear your thoughts: EVIO, Inc. Message Board

• Cannabis deals in Canada cross the billion-dollar mark
• DehydraTech™ offers new and innovative methods of oral delivery
• Committed to high quality products using revolutionary technology
• The only company in the world with patents for this innovative edible technology

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) expects to benefit significantly as cannabis deals in Canada cross the billion-dollar mark in anticipation of the legalization of recreational cannabis, which is only months away (http://ibn.fm/n7ztX). Its newly developed oral digestion technology, DehydraTECH™, is a complementary layer that works with other R&D being done on cannaboids. LXRP has been awarded a patent in the U.S. and Australia, with patents pending in 40 more countries, for the improved delivery (oral or ingestible) of all non-psychoactive cannabinoids. As the only company in the world with patents for this innovative edible technology, LXRP is in a unique position to work alongside other cannabis industry players, creating partnerships rather than competitors.

DehydraTECH allows for faster delivery time, lower dosages and shorter treatment regimens. Oral ingestion of the client drug eliminates unhealthy practices of inhalation dosing. It improves the absorption rate, by as much as five to 10 times, of non-steroid anti-inflammatory drugs (NSAIDs), vitamins, cannabinoids and even nicotine. Delivery time, the time it takes from ingestion to payload molecules reaching the bloodstream, is reduced from the 60-90 minutes of current methods to a mere 15-25 minutes. High concentrations of unhealthy sugars or sweeteners are no longer needed to mask the bitter taste, and side effects are reduced, improving the bioavailability of its client drug. This provides an opportunity for new and innovative methods of oral delivery.

LXRP is committed to finding new ways to partner with companies in order to deliver high quality products, leveraging its technology that allows Lexaria to partner with, instead of compete against, other successful names in the cannabis industry. Recently, LXRP partnered with Cannfections Group Inc. to create high quality chocolate edibles using its oral technology. It continues to develop quality product lines in sports nutrition, teas, tablets, pills and beverages, using DehydraTech for optimal delivery.

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Stock price increased by more than $3.00 in a two-month period
• Various acquisitions and partnerships in 2018
• Focused on incubating the new century’s technology giants

From numerous recent acquisitions to a stock price that has climbed dramatically in the past year, it’s an exciting time for blockchain-focused venture builder Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8).

Engaged in funding and empowering entrepreneurs to implement cutting-edge blockchain solutions, Victory Square is in the business of incubating a new generation of technology titans. The company’s diversified portfolio includes investment interests in the gaming, health care, artificial intelligence and virtual reality sectors, as well as others, and Victory Square’s portfolio companies are effectively disrupting a wide range of sectors across the global economy.

So far in 2018, Victory Square has announced various important acquisitions, including a 100 percent acquisition of established mobile games studio V2 Games Inc. (http://ibn.fm/PlGkn), a 31.35 percent acquisition of emerging payment processing company PayVida Solutions Inc. (http://ibn.fm/Viecy), and a 23.1 percent acquisition of emerging blockchain-focused fintech company Cassia Research Inc. (http://ibn.fm/AlbwZ). The company has further forged various exciting strategic partnerships this year.

Victory Square’s stock has enjoyed an impressive boost in a short amount of time, climbing from $0.298 in October 2017 to an impressive $3.32 by December 2017. As of February 27, the company’s price has remained well above $2.00 per share.

Victory Square operates on the idea that impactful companies are built upon experimentation of bold ideas, and entrepreneurs working with the company have invaluable access to Victory Square’s education programs, global mentor network, distribution partners, creative workspaces, operational support and other resources to help them scale on an international level.

The company’s impressive brag sheet includes assisting more than 1,000 entrepreneurs and more than 500 startups to date, helping these entities collectively raise over $100 million and create more than 1,000 jobs.

Victory Square recognizes blockchain as the new major technology and the next key platform for innovation, with the ability to revolutionize the interconnections and operations of business and social structures. Leveraging its extensive expertise and standout prowess in building companies, Victory Square is hard at work identifying, incubating, advising and investing in the industry’s very best blockchain entrepreneurs.

For more information, visit the company’s website at www.VictorySquare.com

• ChineseInvestors.com provides first platform for Chinese-centric CBD market
• The company boasts real-time services in Chinese character sets
• ChineseInvestors.com launched CBD navigation application

Founded in 1999, ChineseInvestors.com, Inc. (OTCQB: CIIX) aims to be a leading financial information website that provides real-time market commentary, analysis and education-related services to Chinese-speaking investors through its dynamic financial website, www.Chinesefn.com. ChineseInvestors.com, Inc. went public on the OTCQB Venture Market in January 2012, under the symbol CIIX (http://ibn.fm/MrTES).

Having recognized the unprecedented opportunities that lie within the American cannabis industry, the company started laying the foundations to capitalize on the ever-growing demand for cannabidiol-based nutrition and health products. The end of 2016 marked the company’s implementation of plans for its new website, its mobile application and its online distribution of CBD oils for the booming global industry of medical marijuana. Although marijuana use is illegal within the borders of China, cannabis-based oils that include hemp-based CBDs are legal. This unique opportunity opens a potential market of nearly two billion people for the company.

Following the launch of ChineseCBDoil.com in early 2017, the company noted that it was the first online CBD health products store in the Chinese language. The website shows a variety of nutritional supplements containing CBD, including soft gels, capsules and concentrates marketed to Chinese-speaking customers worldwide. It is the company’s intention to open up a retail store in the predominantly Chinese community of San Gabriel, California, which is also where the company’s headquarters is located (http://ibn.fm/AGXuh).

ChineseInvestors.com also launched the world’s first Chinese-language-based mobile cannabis navigation application. This ‘Yelp’ style social media application is set to contain a database of marijuana dispensaries and cannabis strains, along with platforms to review and discuss various cannabis products and maps that show the locations of medical and recreational cannabis dispensaries. Alongside this, the application is set to offer cannabis business summaries and reports from Los Angeles, as well as other large cities, in an effort to provide customers with access to the best recommendations for local marijuana products. The application has been approved by the Apple store and is available for download.

In an effort to assist patients with Alzheimer’s disease, epilepsy, cirrhosis of the liver and a range of other physical and mental ailments, ChineseInvestors.com will continue its focus on investment in both the distribution and the R&D of CBD medicine and health products. With the company’s base of over 100,000 users, alongside its brand value built over the past 18 years, its mission is to become the leading Chinese medical marijuana-focused publicly traded company.

China has nearly 10 million patients that suffer from epilepsy, placing it among the most common diseases that Chinese researchers are eager to cure. Currently, in China, epilepsy cannot be wholly cured, with patients relying heavily on drugs or Chinese herbs to temporarily control the illness. In the United States, epilepsy has been successfully addressed through specialized surgical treatment. However, this option comes with a high risk factor. As a result, a majority of Chinese patients are inclined to seek conservative treatment methods in the field of Western medicine. CBD oil, therefore, has a huge potential within the market space for the treatment of epileptic cases that are located in the mainland or overseas.

Regarding clinical trials and research, ChineseInvestors.com intends to further study the efficacy of CBD oil for the treatment of the above-mentioned illnesses. Apart from that, the company will invest in CBD drug R&D enterprises with the goal of developing various CBD drugs that show positive results when used to combat epilepsy and Alzheimer’s disease. The application period for new drugs of this nature in China is two to four years, which is notably shorter than that of the FDA. It is the company’s goal to be the first company in China to use CBD oil to help mitigate the suffering of patients with epilepsy and Alzheimer’s disease.

The company also offers support services to its various partners, consultative services to smaller private companies that are considering becoming public entities and advertising and public relations-related support services.

With the further legalization of medical marijuana supported by studies, greater market sizes can be expected. With fewer drug side effects and further drug development, it is likely that the number of CBD products will increase, with more people likely to opt for these safer treatments. On a wider scale the problem of acute and chronic pain can be combatted, resulting in fewer production losses in the workplace.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board